CAS: 185629-32-7; Methyl 4-Amino-3-Fluorobenzoate

上下游产品

3-氟-4-氨基苯甲酸 4-Amino-3-Fluorobenzoic Acid 455-87-8
3-氟-4-硝基苯甲酸甲酯 Methyl 3-Fluoro-4-Nitrobenzoate 185629-31-6
3-氟-4-硝基苯甲酸 3-Fluoro-4-Nitrobenzoic Acid 403-21-4
3,4-二氟苯甲酸甲酯 Methyl 3,4-Difluorobenzoate 369-25-5
4-氯-3-氟苯甲酸甲酯 Methyl 4-Chloro-3-Fluorobenzoate 206362-87-0

📜3,4-二氟苯甲酸甲酯置于dipotassium Peroxodisulfate,Sodium Azide,水,Silver Carbonate体系中,用 N,N-二甲基甲酰胺 用作溶剂,以87%的收率获得4-氨基-3-氟苯羧酸甲酯
参考文献:银催化氟代芳烃的分子间胺化
标题:银催化氟代芳烃的分子间胺化
摘要:已经开发了新颖的高选择性的ag催化的氟代芳烃的分子间胺化.这种转变从容易获得的4-羰基氟苯和nan 3或其他氮源开始,通过胺化,然后进行cf键断裂,从而在温和的条件下提供所需的4-羰基芳胺产品.用少量水促进反应.该途径不同于先前报道的自由基胺化反应.
Doi:10.1039/c8Ob01749B

专利信息

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:US-2018370905-A1
优先权日:2013-04-05
标题:Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same

专利号:US-2016046560-A1
优先权日:2013-04-05
标题 :Compounds useful for the treatment of metabolic disorders and synthesis of the same

专利号:WO-2014165816-A1
优先权日:2013-04-05
标 题 :Compounds useful for the treatment of metabolic disorders and synthesis of the same

专利号:US-9700543-B2
优先权日:2011-05-31
标题 :GLP-1 receptor stabilizers and modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; BRAHMACHARY ENUGURTHI; YEAGER ADAM RICHARD
权利人:CELGENE INT II SÀRL
摘要:Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.